Protocol Ledger

NCT03547206 · Phase II · TERMINATED

Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Interventional Phase II clinical trial protocol NCT03547206 sponsored by Regenera Pharma in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-07-10 Enrollment: 165 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03547206
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)165 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03547206
Protocol FieldVerified Registry Value
NCT IdentifierNCT03547206
Consolidated Lead SponsorRegenera Pharma
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment165 participants (ACTUAL)
Registered Start Date2018-07-10
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI